Physician profile
Cara D Hamm
NPI 1710172507
$4,026.37
in general payments reported to CMS, 2019-2025
20 companies · $669 in 2025
The $669 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $198 · 2021: $531 · 2022: $762 · 2023: $750 · 2024: $786 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,206.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $881.02 | 2019-2025 | Cequa |
| Abbvie INC. | $683.47 | 2022-2025 | |
| Allergan, INC. | $588.34 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $569.55 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $381.55 | 2021-2025 | Rocklatan, Tryptyr, Rhopressa |
| Oyster Point Pharma, INC. | $173.42 | 2022-2024 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $168.75 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $117.19 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $103.00 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $76.85 | 2019-2021 | |
| Thea Pharma INC. | $55.99 | 2023-2024 | Iyuzeh |
| Johnson & Johnson Vision Care, INC. | $40.11 | 2022 | |
| Kala Pharmaceuticals, INC. | $37.87 | 2021-2022 | |
| Coopervision INC. | $25.58 | 2019-2023 | Myday Contact Lens |
| Harrow Eye, LLC | $23.94 | 2024 | Vevye |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.57 | 2025 | Izervay |
| Maculogix, INC. | $20.12 | 2019 | |
| Dompe US, INC. | $19.22 | 2025 | Oxervate |
| Shire North American Group INC | $18.54 | 2019 | |
| Eyevance Pharmaceuticals LLC | $18.29 | 2023 | Flarex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Hamm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.